Literature DB >> 8862943

The aetiology and management of erectile, ejaculatory, and fertility problems in men with diabetes mellitus.

W D Dunsmuir1, S A Holmes.   

Abstract

Erectile impotence is more common in the diabetic than the general population, occurs at a younger age, and is often associated with ejaculatory problems. For these, and possibly for other more subtle reasons, fertility may be a problem for men with diabetes. The symptoms of erectile and ejaculatory dysfunction are frequently not discussed between patient and doctor. Psychological factors are important but the vast majority of diabetic patients have an organic basis for their impotence. Both neurogenic and vascular factors are important in the pathogenesis of erectile failure. Autonomic neuropathy is almost certainly the cause of the ejaculatory failure that may be present in up to 40% of men with diabetes. The final biochemical mediator of erection within the penile erectile tissue is nitric oxide and a key enzyme in its degradation is phosphodiesterase (type V). Drugs that affect the metabolism of this enzyme are being developed to treat erectile failure. At present, the self injection of intra-cavernosal erectogenic agents (such as prostaglandin E1) provide the main form of therapy for erectile failure. Vacuum devices are a simple alternative and venous ligation surgery may be effective for a properly selected cohort of patients. Prosthetic implants are a final option for patients in whom all else has failed. Fertility problems, particularly when associated with ejaculatory failure can be overcome with modern assisted reproductive techniques. Nowadays, these will frequently involve gamete micro-manipulation.

Entities:  

Mesh:

Year:  1996        PMID: 8862943     DOI: 10.1002/(SICI)1096-9136(199608)13:8<700::AID-DIA174>3.0.CO;2-8

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  25 in total

Review 1.  Ejaculatory disorders: epidemiology and current approaches to definition, classification and subtyping.

Authors:  Emmanuele A Jannini; Andrea Lenzi
Journal:  World J Urol       Date:  2005-05-18       Impact factor: 4.226

2.  Stem cell treatment for complicated diabetes.

Authors:  Jong Yoon Bahk; Hoon Han; Youn Soo Lee
Journal:  Int J Stem Cells       Date:  2008-11       Impact factor: 2.500

Review 3.  A step-wise approach to sperm retrieval in men with neurogenic anejaculation.

Authors:  Mikkel Fode; Dana A Ohl; Jens Sønksen
Journal:  Nat Rev Urol       Date:  2015-10-20       Impact factor: 14.432

Review 4.  How well tolerated are lipid-lowering drugs?

Authors:  B Tomlinson; P Chan; W Lan
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

5.  Smooth muscle myosin expression, isoform composition, and functional activities in rat corpus cavernosum altered by the streptozotocin-induced type 1 diabetes.

Authors:  Xinhua Zhang; Nirmala D Kanika; Arnold Melman; Michael E DiSanto
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-09-13       Impact factor: 4.310

6.  Prolactinoma in a diabetic dialysis patient with erectile dysfunction: a difficult differential diagnosis.

Authors:  Giorgina B Piccoli; Francesca Bermont; Andrea Magnano; Giorgio Soragna; Massimo Terzolo
Journal:  Rev Diabet Stud       Date:  2007-02-10

7.  Is male fertility associated with type 2 diabetes mellitus?

Authors:  Abdulbari Bener; Abdulla A Al-Ansari; Mahmoud Zirie; Abdulla O A A Al-Hamaq
Journal:  Int Urol Nephrol       Date:  2009-04-21       Impact factor: 2.370

8.  ROS activates JNK-mediated autophagy to counteract apoptosis in mouse mesenchymal stem cells in vitro.

Authors:  Guan-yu Liu; Xiao-xue Jiang; Xin Zhu; Wei-yang He; You-lin Kuang; Ke Ren; Yong Lin; Xin Gou
Journal:  Acta Pharmacol Sin       Date:  2015-11-23       Impact factor: 6.150

Review 9.  Ejaculatory disorders and lower urinary tract symptoms.

Authors:  Robert E Brannigan
Journal:  Curr Urol Rep       Date:  2004-08       Impact factor: 3.092

Review 10.  Disorders of ejaculation.

Authors:  E A Jannini; C Simonelli; A Lenzi
Journal:  J Endocrinol Invest       Date:  2002-12       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.